儿童用药的"良药不苦口"一直是业界的追求。玉森新药研发团队以患儿为中心，将中药口服液的口感 差、低载药量、产品稳定性差易出沉淀这三大核心难题作为攻关重点。通过技术创新，显著提高中药口 服液口感，提高儿童服药顺应性，减轻家长喂药负担，提高中药口服液载药量的同时保障产品有效期内 无沉淀。 消腺止鼾口服液从立项到工艺开发，全程由玉森新药自主完成，在完成关键技术攻关与成果积累后，与 四川现代中药创新技术有限公司共同推动成果产业化，实现了研发价值的高效转化。 苏州玉森新药开发有限公司(以下简称"玉森新药")在新药研发方面"双喜临门（603008）"。作为一家专 注于中药创新研发的高新技术企业，苏州玉森以临床价值为导向，致力于中药现代化研究和创新药物开 发。多年来，公司在儿科、呼吸科、心脑血管等领域积累了丰富的研发经验，形成从药物发现、临床前 研究到产业化开发的完整创新体系。 就在12月3日，由玉森新药立项并研发的创新中药——消腺止鼾口服液正式获得国家药品监督管理局的 临床试验批件，标志着国内腺样体肥大儿童患者将迎来首个具有明确中医理论支持、口感良好、质量稳 定的中药口服液，这一里程碑成果展现出玉森新药在新药研发领域深厚 ...

Group 1 - The core viewpoint of the article highlights the strategic partnership between Suzhou Yusen Pharmaceutical Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. to develop innovative traditional Chinese medicine products [1] - The collaboration focuses on two innovative TCM products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules," aiming to enhance the research and industrialization of TCM [1] - The partnership aims to integrate technology, clinical, and industrial resources to cover the entire chain of preclinical research, clinical research, registration, and post-market promotion [1] Group 2 - Yusen Pharmaceutical emphasizes the combination of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. plans to deepen exploration in areas such as international registration of TCM and the development of health products [2] - The collaboration is expected to contribute to the construction of a Sino-Sichuan TCM innovation corridor, facilitating the global market entry of Chinese TCM new drugs [2]

Core Insights - Suzhou Yusen Pharmaceutical Development Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. signed a product cooperation agreement to collaborate on two innovative traditional Chinese medicine products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules" [1][2] - The partnership aims to enhance the research and industrialization of traditional Chinese medicine, integrating resources across technology, clinical research, registration, and post-market promotion [1][2] Group 1 - "Xiaoxian Zhihuan Oral Liquid" targets children aged 3-7 with adenoid hypertrophy, utilizing ingredients like Platycodon and Houttuynia to clear heat and resolve phlegm, filling a gap in the traditional Chinese medicine market [2] - "Tiandan Dingxuan Granules" is designed for treating dizziness caused by phlegm and wind, featuring core ingredients such as Gastrodia and Salvia, addressing the growing demand for dizziness treatment in an aging population [2] - Both products are expected to enter clinical trials by 2026, targeting a market of 4 billion for adenoid hypertrophy and 1.2 billion for dizziness, showcasing the unique characteristics of traditional Chinese medicine with minimal side effects [2] Group 2 - The collaboration is seen as a synergy of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Future plans include exploring international registration of traditional Chinese medicine and the development of health products, contributing to the construction of a collaborative innovation corridor between Sichuan and Suzhou [2]